Daily Stock Analysis, ALNY, Alnylam Pharmaceuticals Inc, priceseries

Alnylam Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
96.19
Close
94.73
High
97.15
Low
94.48
Previous Close
95.86
Daily Price Gain
-1.13
YTD High
153.99
YTD High Date
Mar 20, 2018
YTD Low
93.01
YTD Low Date
Apr 6, 2018
YTD Price Change
-37.12
YTD Gain
-28.15%
52 Week High
153.99
52 Week High Date
Mar 20, 2018
52 Week Low
50.39
52 Week Low Date
Apr 25, 2017
52 Week Price Change
43.38
52 Week Gain
84.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 24. 2017
46.62
Mar 13. 2017
50.52
11 Trading Days
8.37%
Link
LONG
May 12. 2017
56.77
May 26. 2017
67.35
10 Trading Days
18.64%
Link
LONG
Jun 1. 2017
69.70
Jun 27. 2017
80.59
18 Trading Days
15.62%
Link
LONG
Mar 7. 2018
123.99
Mar 23. 2018
139.26
12 Trading Days
12.31%
Link
Company Information
Stock Symbol
ALNY
Exchange
NasdaqGS
Company URL
http://www.alnylam.com
Company Phone
(617) 551-8200
CEO
John M. Maraganore
Headquarters
Massachusetts
Business Address
300 THIRD STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178670
About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.